Ionis Pharmaceuticals, Inc. (IONS)
USD 27.15
(-4.8%)
USD 27.15
(-4.8%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 1.05 Billion USD | 264.22% |
| 2022 | -642 Million USD | 32.7% |
| 2021 | -954 Million USD | 16.54% |
| 2020 | -1.14 Billion USD | 36.15% |
| 2019 | -1.79 Billion USD | -18.09% |
| 2018 | -1.51 Billion USD | -209.61% |
| 2017 | -489.6 Million USD | -197.47% |
| 2016 | -164.58 Million USD | 56.87% |
| 2015 | -381.6 Million USD | -8.0% |
| 2014 | -353.33 Million USD | 30.23% |
| 2013 | -506.42 Million USD | -119.75% |
| 2012 | -230.45 Million USD | -250.27% |
| 2011 | 153.36 Million USD | 81.81% |
| 2010 | 84.35 Million USD | 189.95% |
| 2009 | -93.77 Million USD | -116.0% |
| 2008 | -43.41 Million USD | -237.89% |
| 2007 | 31.48 Million USD | 21.93% |
| 2006 | 25.82 Million USD | -82.08% |
| 2005 | 144.1 Million USD | -34.47% |
| 2004 | 219.9 Million USD | 11.77% |
| 2003 | 196.75 Million USD | 55.13% |
| 2002 | 126.83 Million USD | 1385.88% |
| 2001 | 8.53 Million USD | -87.31% |
| 2000 | 67.24 Million USD | 20.3% |
| 1999 | 55.9 Million USD | 4.1% |
| 1998 | 53.7 Million USD | 159.42% |
| 1997 | 20.7 Million USD | 288.18% |
| 1996 | -11 Million USD | 70.11% |
| 1995 | -36.8 Million USD | -2966.67% |
| 1994 | -1.2 Million USD | 94.0% |
| 1993 | -20 Million USD | -440.54% |
| 1992 | -3.7 Million USD | 75.66% |
| 1991 | -15.2 Million USD | -2433.33% |
| 1990 | -600 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 1.68 Billion USD | 3.88% |
| 2024 Q1 | 1.62 Billion USD | 53.68% |
| 2023 Q3 | 1.05 Billion USD | 0.26% |
| 2023 Q2 | 1.04 Billion USD | -0.26% |
| 2023 Q1 | 1.05 Billion USD | 263.86% |
| 2023 FY | 1.05 Billion USD | 264.22% |
| 2023 Q4 | 1.05 Billion USD | 0.22% |
| 2022 Q4 | -642 Million USD | -170.6% |
| 2022 Q3 | 909.4 Million USD | 29.66% |
| 2022 Q1 | 679.7 Million USD | 171.25% |
| 2022 FY | -642 Million USD | 32.7% |
| 2022 Q2 | 701.39 Million USD | 3.19% |
| 2021 FY | -954 Million USD | 16.54% |
| 2021 Q2 | 715.39 Million USD | 44.34% |
| 2021 Q1 | 495.63 Million USD | 143.36% |
| 2021 Q4 | -954 Million USD | -246.98% |
| 2021 Q3 | 649.04 Million USD | -9.27% |
| 2020 FY | -1.14 Billion USD | 36.15% |
| 2020 Q4 | -1.14 Billion USD | -789.09% |
| 2020 Q2 | 259 Million USD | -11.72% |
| 2020 Q1 | 293.39 Million USD | 116.39% |
| 2020 Q3 | 165.87 Million USD | -35.96% |
| 2019 Q4 | -1.79 Billion USD | -538.39% |
| 2019 Q1 | 261.46 Million USD | 117.25% |
| 2019 Q2 | -1.67 Billion USD | -740.62% |
| 2019 FY | -1.79 Billion USD | -18.09% |
| 2019 Q3 | 408.31 Million USD | 124.38% |
| 2018 Q4 | -1.51 Billion USD | -1189.62% |
| 2018 Q3 | 139.11 Million USD | 171.21% |
| 2018 Q1 | -493.66 Million USD | -0.83% |
| 2018 FY | -1.51 Billion USD | -209.61% |
| 2018 Q2 | -195.35 Million USD | 60.43% |
| 2017 Q4 | -489.6 Million USD | -215.12% |
| 2017 Q1 | 466.58 Million USD | 383.49% |
| 2017 FY | -489.6 Million USD | -197.47% |
| 2017 Q3 | 425.31 Million USD | 225.4% |
| 2017 Q2 | -339.17 Million USD | -172.69% |
| 2016 FY | -164.58 Million USD | 56.87% |
| 2016 Q1 | -308.34 Million USD | 19.2% |
| 2016 Q2 | 361.42 Million USD | 217.21% |
| 2016 Q3 | 396.05 Million USD | 9.58% |
| 2016 Q4 | -164.58 Million USD | -141.56% |
| 2015 Q3 | 337.38 Million USD | 191.53% |
| 2015 Q1 | 304.35 Million USD | 186.14% |
| 2015 Q4 | -381.6 Million USD | -213.11% |
| 2015 Q2 | -368.61 Million USD | -221.11% |
| 2015 FY | -381.6 Million USD | -8.0% |
| 2014 Q3 | 153.83 Million USD | 17.32% |
| 2014 Q4 | -353.33 Million USD | -329.69% |
| 2014 FY | -353.33 Million USD | 30.23% |
| 2014 Q2 | 131.12 Million USD | 112.79% |
| 2014 Q1 | 61.62 Million USD | 112.17% |
| 2013 Q3 | -36.6 Million USD | 53.39% |
| 2013 Q4 | -506.42 Million USD | -1283.45% |
| 2013 Q1 | 108.61 Million USD | 147.13% |
| 2013 FY | -506.42 Million USD | -119.75% |
| 2013 Q2 | -78.53 Million USD | -172.3% |
| 2012 Q3 | 141.89 Million USD | -2.41% |
| 2012 FY | -230.45 Million USD | -250.27% |
| 2012 Q4 | -230.45 Million USD | -262.41% |
| 2012 Q1 | 163.9 Million USD | 6.88% |
| 2012 Q2 | 145.4 Million USD | -11.29% |
| 2011 Q3 | 157.59 Million USD | 35.58% |
| 2011 Q2 | 116.23 Million USD | 68.48% |
| 2011 Q1 | 68.99 Million USD | -18.21% |
| 2011 FY | 153.36 Million USD | 81.81% |
| 2011 Q4 | 153.36 Million USD | -2.69% |
| 2010 Q1 | 43.01 Million USD | 148.06% |
| 2010 FY | 84.35 Million USD | 189.95% |
| 2010 Q4 | 84.35 Million USD | 86.58% |
| 2010 Q2 | 103.61 Million USD | 140.87% |
| 2010 Q3 | 45.21 Million USD | -56.37% |
| 2009 FY | -93.77 Million USD | -116.0% |
| 2009 Q2 | -80.68 Million USD | 32.82% |
| 2009 Q3 | -136.76 Million USD | -69.5% |
| 2009 Q4 | -89.5 Million USD | 34.55% |
| 2009 Q1 | -120.09 Million USD | -176.63% |
| 2008 Q1 | -103.57 Million USD | -428.95% |
| 2008 Q4 | -43.41 Million USD | 55.11% |
| 2008 Q3 | -96.7 Million USD | 64.72% |
| 2008 Q2 | -274.13 Million USD | -164.68% |
| 2008 FY | -43.41 Million USD | -237.89% |
| 2007 FY | 31.48 Million USD | 21.93% |
| 2007 Q1 | 73.27 Million USD | 183.76% |
| 2007 Q2 | 41.06 Million USD | -43.96% |
| 2007 Q3 | 69.78 Million USD | 69.94% |
| 2007 Q4 | 31.48 Million USD | -54.88% |
| 2006 Q2 | 38.55 Million USD | -73.24% |
| 2006 FY | 25.82 Million USD | -82.08% |
| 2006 Q4 | 25.82 Million USD | -32.37% |
| 2006 Q3 | 38.18 Million USD | -0.97% |
| 2006 Q1 | 144.09 Million USD | -0.0% |
| 2005 Q1 | 241.02 Million USD | 9.6% |
| 2005 Q3 | 96.93 Million USD | -60.52% |
| 2005 Q4 | 144.1 Million USD | 48.65% |
| 2005 Q2 | 245.55 Million USD | 1.88% |
| 2005 FY | 144.1 Million USD | -34.47% |
| 2004 Q3 | 217.95 Million USD | 6.88% |
| 2004 Q4 | 219.9 Million USD | 0.9% |
| 2004 Q1 | 190.15 Million USD | -3.35% |
| 2004 FY | 219.9 Million USD | 11.77% |
| 2004 Q2 | 203.92 Million USD | 7.24% |
| 2003 Q4 | 196.75 Million USD | 11.55% |
| 2003 FY | 196.75 Million USD | 55.13% |
| 2003 Q3 | 176.38 Million USD | 40.84% |
| 2003 Q2 | 125.23 Million USD | -21.46% |
| 2003 Q1 | 159.46 Million USD | 25.72% |
| 2002 Q2 | 91.38 Million USD | 79.11% |
| 2002 Q4 | 126.83 Million USD | 31.81% |
| 2002 FY | 126.83 Million USD | 1385.88% |
| 2002 Q1 | 51.01 Million USD | 497.69% |
| 2002 Q3 | 96.22 Million USD | 5.3% |
| 2001 Q4 | 8.53 Million USD | -93.85% |
| 2001 FY | 8.53 Million USD | -87.31% |
| 2001 Q3 | 138.83 Million USD | 20.0% |
| 2001 Q2 | 115.69 Million USD | 14.78% |
| 2001 Q1 | 100.79 Million USD | 49.89% |
| 2000 Q1 | 30.33 Million USD | -45.74% |
| 2000 FY | 67.24 Million USD | 20.3% |
| 2000 Q2 | 36.18 Million USD | 19.3% |
| 2000 Q3 | 40.83 Million USD | 12.86% |
| 2000 Q4 | 67.24 Million USD | 64.67% |
| 1999 Q3 | 51.5 Million USD | 0.0% |
| 1999 Q2 | 51.5 Million USD | -17.2% |
| 1999 Q4 | 55.9 Million USD | 8.54% |
| 1999 Q1 | 62.2 Million USD | 15.83% |
| 1999 FY | 55.9 Million USD | 4.1% |
| 1998 Q1 | 31.1 Million USD | 50.24% |
| 1998 Q4 | 53.7 Million USD | 40.94% |
| 1998 Q3 | 38.1 Million USD | 8.24% |
| 1998 FY | 53.7 Million USD | 159.42% |
| 1998 Q2 | 35.2 Million USD | 13.18% |
| 1997 Q1 | -400 Thousand USD | 96.36% |
| 1997 Q3 | 6.7 Million USD | 937.5% |
| 1997 FY | 20.7 Million USD | 288.18% |
| 1997 Q4 | 20.7 Million USD | 208.96% |
| 1997 Q2 | -800 Thousand USD | -100.0% |
| 1996 Q3 | -15.7 Million USD | -0.64% |
| 1996 Q2 | -15.6 Million USD | -27.87% |
| 1996 FY | -11 Million USD | 70.11% |
| 1996 Q1 | -12.2 Million USD | 66.85% |
| 1996 Q4 | -11 Million USD | 29.94% |
| 1995 Q4 | -36.8 Million USD | -146.98% |
| 1995 Q2 | -8.4 Million USD | -50.0% |
| 1995 Q3 | -14.9 Million USD | -77.38% |
| 1995 Q1 | -5.6 Million USD | -366.67% |
| 1995 FY | -36.8 Million USD | -2966.67% |
| 1994 Q1 | -20.3 Million USD | -1.5% |
| 1994 FY | -1.2 Million USD | 94.0% |
| 1994 Q4 | -1.2 Million USD | 70.0% |
| 1994 Q2 | -6.3 Million USD | 68.97% |
| 1994 Q3 | -4 Million USD | 36.51% |
| 1993 Q2 | -12 Million USD | 33.7% |
| 1993 FY | -20 Million USD | -440.54% |
| 1993 Q3 | -6.8 Million USD | 43.33% |
| 1993 Q4 | -20 Million USD | -194.12% |
| 1993 Q1 | -18.1 Million USD | -389.19% |
| 1992 Q2 | -1 Million USD | 81.13% |
| 1992 FY | -3.7 Million USD | 75.66% |
| 1992 Q1 | -5.3 Million USD | 65.13% |
| 1992 Q3 | -1.4 Million USD | -40.0% |
| 1992 Q4 | -3.7 Million USD | -164.29% |
| 1991 FY | -15.2 Million USD | -2433.33% |
| 1991 Q3 | -11.6 Million USD | 57.82% |
| 1991 Q4 | -15.2 Million USD | -31.03% |
| 1991 Q1 | -14.2 Million USD | -2266.67% |
| 1991 Q2 | -27.5 Million USD | -93.66% |
| 1990 Q4 | -600 Thousand USD | 0.0% |
| 1990 FY | -600 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AbCellera Biologics Inc. | -55.94 Million USD | 1984.65% |
| Alkermes plc | -166.73 Million USD | 732.289% |
| Agenus Inc. | 274.13 Million USD | -284.58% |
| Alnylam Pharmaceuticals, Inc. | 1.86 Billion USD | 43.62% |
| Aptorum Group Limited | 1.35 Million USD | -77588.818% |
| Ardelyx, Inc. | 34.51 Million USD | -2954.801% |
| Arrowhead Pharmaceuticals, Inc. | 4.28 Million USD | -24532.547% |
| Bicycle Therapeutics plc | -481.46 Million USD | 318.971% |
| BioXcel Therapeutics, Inc. | 36.16 Million USD | -2815.336% |
| ChromaDex Corporation | -24.04 Million USD | 4484.036% |
| Chimerix, Inc. | -25.51 Million USD | 4231.649% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | -15030.045% |
| Caribou Biosciences, Inc. | -23.67 Million USD | 4552.73% |
| CRISPR Therapeutics AG | -150.84 Million USD | 798.911% |
| Precision BioSciences, Inc. | -85.41 Million USD | 1334.367% |
| Dyadic International, Inc. | -6.37 Million USD | 16629.58% |
| Eton Pharmaceuticals, Inc. | -15.93 Million USD | 6716.915% |
| Fortress Biotech, Inc. | 7.66 Million USD | -13654.377% |
| Lantern Pharma Inc. | -21.7 Million USD | 4957.667% |
| HOOKIPA Pharma Inc. | -110.53 Million USD | 1053.774% |
| Inhibikase Therapeutics, Inc. | -8.54 Million USD | 12440.528% |
| Incyte Corporation | -3.17 Billion USD | 133.205% |
| IO Biotech, Inc. | -140.69 Million USD | 849.311% |
| Jaguar Health, Inc. | 29.39 Million USD | -3487.061% |
| Novavax, Inc. | -298.29 Million USD | 453.434% |
| Janux Therapeutics, Inc. | 5.33 Million USD | -19654.038% |
| Opthea Limited | 28.15 Million USD | -3644.207% |
| Ligand Pharmaceuticals Incorporated | -16.78 Million USD | 6379.546% |
| ContextLogic Inc. | -232 Million USD | 554.428% |
| MiMedx Group, Inc. | -33.9 Million USD | 3209.858% |
| Pyxis Oncology, Inc. | 10.19 Million USD | -10241.079% |
| TransCode Therapeutics, Inc. | -2.31 Million USD | 45601.11% |
| NextCure, Inc. | -6.47 Million USD | 16377.181% |
| Ocuphire Pharma, Inc. | -50.5 Million USD | 2187.628% |
| Oncternal Therapeutics, Inc. | -6.37 Million USD | 16627.246% |
| Outlook Therapeutics, Inc. | 12.16 Million USD | -8567.679% |
| Vaxcyte, Inc. | -368.22 Million USD | 386.311% |
| PDS Biotechnology Corporation | -32.7 Million USD | 3323.199% |
| Madrigal Pharmaceuticals, Inc. | 17.27 Million USD | -6001.823% |
| Pharming Group N.V. | 109.8 Million USD | -860.141% |
| Pieris Pharmaceuticals, Inc. | -17.39 Million USD | 6160.433% |
| Avidity Biosciences, Inc. | -175.23 Million USD | 701.651% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | 5792.663% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | 5792.663% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | 14948.915% |
| Sol-Gel Technologies Ltd. | -5.86 Million USD | 18091.007% |
| Acelyrin, Inc. | -216.9 Million USD | 586.057% |
| Salarius Pharmaceuticals, Inc. | -5.61 Million USD | 18891.851% |
| SELLAS Life Sciences Group, Inc. | -1.72 Million USD | 61252.726% |
| Summit Therapeutics Inc. | 34.67 Million USD | -2940.529% |
| Sensei Biotherapeutics, Inc. | -6.8 Million USD | 15597.178% |
| Senti Biosciences, Inc. | 1.74 Million USD | -60490.402% |
| Stoke Therapeutics, Inc. | -184.6 Million USD | 671.09% |
| Syros Pharmaceuticals, Inc. | -77.45 Million USD | 1461.213% |
| Alaunos Therapeutics, Inc. | -6.06 Million USD | 17491.504% |
| Telomir Pharmaceuticals, Inc. Common Stock | 99.76 Thousand USD | -1056614.009% |
| Entrada Therapeutics, Inc. | 628 Thousand USD | -167777.866% |
| VistaGen Therapeutics, Inc. | -117.04 Million USD | 1000.734% |
| Wave Life Sciences Ltd. | -168.23 Million USD | 726.674% |
| Sorrento Therapeutics, Inc. | 110.87 Million USD | -850.909% |
| TRACON Pharmaceuticals, Inc. | -7.59 Million USD | 13979.318% |
| Barinthus Biotherapeutics plc | -129.11 Million USD | 916.544% |
| Psyence Biomedical Ltd. | 6.89 Million USD | -15191.29% |
| Phathom Pharmaceuticals, Inc. | -242.36 Million USD | 534.998% |
| Immix Biopharma, Inc. | -17.5 Million USD | 6121.048% |
| Keros Therapeutics, Inc. | -316.7 Million USD | 432.89% |
| MEI Pharma, Inc. | -3.7 Million USD | 28555.412% |
| Windtree Therapeutics, Inc. | 12.51 Million USD | -8326.768% |
| Xeris Biopharma Holdings, Inc. | 161.74 Million USD | -551.824% |
| Rigel Pharmaceuticals, Inc. | 27.79 Million USD | -3693.304% |
| Fortress Biotech, Inc. | 7.66 Million USD | -13654.377% |
| Precigen, Inc. | -481 Thousand USD | 219283.576% |
| Clearside Biomedical, Inc. | 14.08 Million USD | -7387.203% |
| AlloVir, Inc. | -62.69 Million USD | 1781.671% |
| C4 Therapeutics, Inc. | -55.61 Million USD | 1995.697% |
| Fate Therapeutics, Inc. | 61.66 Million USD | -1609.65% |
| ImmuCell Corporation | 10.99 Million USD | -9492.53% |
| IDEAYA Biosciences, Inc. | -154.14 Million USD | 783.944% |
| Onconetix, Inc. | 5.33 Million USD | -19674.65% |
| PureTech Health plc | -167.19 Million USD | 730.557% |
| VYNE Therapeutics Inc. | -30.46 Million USD | 3561.172% |
| Elevation Oncology, Inc. | -19.11 Million USD | 5614.557% |
| Kintara Therapeutics, Inc. | -4.9 Million USD | 21576.329% |
| Seer, Inc. | -4.24 Million USD | 24964.929% |
| Verrica Pharmaceuticals Inc. | -24.03 Million USD | 4486.042% |
| Innoviva, Inc. | 255.56 Million USD | -312.53% |
| Aadi Bioscience, Inc. | -55.86 Million USD | 1987.214% |
| ESSA Pharma Inc. | -33.62 Million USD | 3235.703% |
| GlycoMimetics, Inc. | -40.98 Million USD | 2672.375% |
| GT Biopharma, Inc. | -1.02 Million USD | 103358.864% |
| Inhibrx Biosciences, Inc. | -67.78 Million USD | 1655.365% |
| Akebia Therapeutics, Inc. | 61.25 Million USD | -1621.065% |
| Catalyst Pharmaceuticals, Inc. | -134.07 Million USD | 886.307% |
| Longboard Pharmaceuticals, Inc. | -13.85 Million USD | 7708.783% |
| Orchestra BioMed Holdings, Inc. | -28.87 Million USD | 3751.541% |
| Alzamend Neuro, Inc. | -75.33 Thousand USD | 1399565.049% |
| Rocket Pharmaceuticals, Inc. | -30.86 Million USD | 3516.088% |
| Aptose Biosciences Inc. | -8.19 Million USD | 12965.057% |
| ZyVersa Therapeutics, Inc. | -3.12 Million USD | 33793.414% |
| Soligenix, Inc. | -4.95 Million USD | 21391.575% |
| Century Therapeutics, Inc. | 847 Thousand USD | -124371.429% |
| Kura Oncology, Inc. | -20.11 Million USD | 5340.446% |
| TScan Therapeutics, Inc. | -40.92 Million USD | 2676.047% |
| Intensity Therapeutics, Inc. | -8.39 Million USD | 12653.858% |
| Ocean Biomedical, Inc. | 1.82 Million USD | -57773.19% |
| CytomX Therapeutics, Inc. | -3.19 Million USD | 33076.947% |
| Autolus Therapeutics plc | -186.59 Million USD | 664.994% |
| Mineralys Therapeutics, Inc. | -49.3 Million USD | 2238.311% |
| EyePoint Pharmaceuticals, Inc. | -275.79 Million USD | 482.268% |
| Eterna Therapeutics Inc. | 34.26 Million USD | -2976.552% |
| Adaptive Biotechnologies Corporation | 164.36 Million USD | -541.41% |
| GRI Bio, Inc. | -1.79 Million USD | 58866.611% |
| Xenetic Biosciences, Inc. | -8.98 Million USD | 11836.253% |
| Tenaya Therapeutics, Inc. | -33.25 Million USD | 3270.078% |
| IGM Biosciences, Inc. | -72.6 Million USD | 1552.047% |
| INmune Bio, Inc. | -25.41 Million USD | 4248.884% |
| Heron Therapeutics, Inc. | 150.95 Million USD | -598.421% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 2181.117% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | 6588.085% |
| Entero Therapeutics, Inc. | -2.88 Million USD | 36644.196% |
| Milestone Pharmaceuticals Inc. | 38.01 Million USD | -2673.308% |
| X4 Pharmaceuticals, Inc. | -41.18 Million USD | 2659.847% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | -3206.486% |
| Coherus BioSciences, Inc. | 377.95 Million USD | -178.944% |
| Verastem, Inc. | -37.27 Million USD | 2928.137% |
| Abeona Therapeutics Inc. | -9.07 Million USD | 11719.894% |
| Pliant Therapeutics, Inc. | -51.86 Million USD | 2132.843% |
| Tonix Pharmaceuticals Holding Corp. | -15.13 Million USD | 7065.795% |
| Histogen Inc. | -7.48 Million USD | 14181.381% |
| Aprea Therapeutics, Inc. | -21.6 Million USD | 4979.353% |
| Surrozen, Inc. | -32.66 Million USD | 3327.63% |
| Organovo Holdings, Inc. | -1.5 Million USD | 70058.394% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | 25180.909% |
| Ovid Therapeutics Inc. | 18.96 Million USD | -5460.451% |
| Panbela Therapeutics, Inc. | 2.61 Million USD | -40200.956% |
| CASI Pharmaceuticals, Inc. | 4.15 Million USD | -25267.493% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.38 Million USD | 12679.097% |
| Centessa Pharmaceuticals plc | -43.44 Million USD | 2526.852% |
| Hepion Pharmaceuticals, Inc. | -14.57 Million USD | 7332.511% |
| Arcturus Therapeutics Holdings Inc. | -316.78 Million USD | 432.8% |
| BioRestorative Therapies, Inc. | -722.06 Thousand USD | 146109.057% |
| Apollomics, Inc. | -27.39 Million USD | 3948.414% |
| Amarin Corporation plc | -191.04 Million USD | 651.86% |
| Mesoblast Limited | 55.96 Million USD | -1783.875% |
| Turnstone Biologics Corp. | -14.58 Million USD | 7328.97% |
| Kymera Therapeutics, Inc. | -25.29 Million USD | 4268.405% |
| Synaptogenix, Inc. | -28.66 Million USD | 3778.36% |
| Tiziana Life Sciences Ltd | -936 Thousand USD | 112736.004% |
| Aurinia Pharmaceuticals Inc. | 48.73 Million USD | -2063.41% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | 122392.826% |
| Monopar Therapeutics Inc. | -7.26 Million USD | 14609.515% |
| Exelixis, Inc. | -73.05 Million USD | 1543.221% |
| Better Therapeutics, Inc. | -860 Thousand USD | 122689.884% |
| Nurix Therapeutics, Inc. | -24.01 Million USD | 4490.426% |
| Apellis Pharmaceuticals, Inc. | -241.37 Million USD | 536.785% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | -143130.77% |
| Dermata Therapeutics, Inc. | -7.43 Million USD | 14273.889% |
| Aridis Pharmaceuticals, Inc. | 1.25 Million USD | -83972.807% |
| Gritstone bio, Inc. | 39.49 Million USD | -2569.721% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 1353.58% |
| TNF Pharmaceuticals, Inc. | -2.63 Million USD | 40153.835% |
| Avid Bioservices, Inc. | 169.72 Million USD | -521.154% |
| Insmed Incorporated | 721.62 Million USD | -46.098% |
| Virpax Pharmaceuticals, Inc. | -9.14 Million USD | 11632.808% |
| MediWound Ltd. | -5.32 Million USD | 19909.714% |
| OmniAb, Inc. | 9.2 Million USD | -11355.754% |
| Alector, Inc. | -35.63 Million USD | 3058.366% |
| Seres Therapeutics, Inc. | 85.97 Million USD | -1126.312% |
| Checkpoint Therapeutics, Inc. | -4.92 Million USD | 21493.527% |
| Viracta Therapeutics, Inc. | 13.23 Million USD | -7863.388% |
| Zai Lab Limited | -775 Million USD | 236.035% |
| Revance Therapeutics, Inc. | 340.55 Million USD | -209.575% |
| Aura Biosciences, Inc. | -21.52 Million USD | 4997.9% |
| Lyell Immunopharma, Inc. | -82.48 Million USD | 1378.217% |
| Immunic, Inc. | -45.34 Million USD | 2425.26% |
| Tarsus Pharmaceuticals, Inc. | -193.21 Million USD | 645.648% |
| Veracyte, Inc. | -203.82 Million USD | 617.247% |
| InMed Pharmaceuticals Inc. | 638.29 Million USD | -65.171% |
| FibroGen, Inc. | 56.76 Million USD | -1757.193% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | -11739.113% |
| Adial Pharmaceuticals, Inc. | -2.82 Million USD | 37391.914% |
| Sonnet BioTherapeutics Holdings, Inc. | -2.07 Million USD | 51022.502% |
| Jazz Pharmaceuticals plc | 4.59 Billion USD | 77.033% |
| Cyclacel Pharmaceuticals, Inc. | -3.34 Million USD | 31655.612% |
| Amylyx Pharmaceuticals, Inc. | -165.96 Million USD | 735.242% |
| TG Therapeutics, Inc. | 17.86 Million USD | -5802.323% |
| Galecto, Inc. | -21.21 Million USD | 5069.235% |
| Calithera Biosciences, Inc. | -23.78 Million USD | 4532.512% |
| Fortrea Holdings Inc. | 1.56 Billion USD | 32.823% |
| KalVista Pharmaceuticals, Inc. | -24.47 Million USD | 4408.079% |
| Aptevo Therapeutics Inc. | -11.5 Million USD | 9262.014% |
| XBiotech Inc. | -200.02 Million USD | 627.076% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 1353.58% |
| Lyra Therapeutics, Inc. | 4.52 Million USD | -23183.414% |
| Foghorn Therapeutics Inc. | -35.26 Million USD | 3089.743% |
| Y-mAbs Therapeutics, Inc. | -77.21 Million USD | 1465.32% |
| Theravance Biopharma, Inc. | 5.69 Million USD | -18425.268% |
| Ultragenyx Pharmaceutical Inc. | -170.41 Million USD | 718.65% |
| Metagenomi, Inc. Common Stock | -92.37 Million USD | 1241.309% |
| Vaxxinity, Inc. | 10.13 Million USD | -10305.379% |
| BioCryst Pharmaceuticals, Inc. | 736.26 Million USD | -43.192% |
| Gain Therapeutics, Inc. | -10.76 Million USD | 9891.205% |
| Cartesian Therapeutics, Inc. | -65.95 Million USD | 1698.449% |
| NexImmune, Inc. | -3.13 Million USD | 33743.686% |
| Creative Medical Technology Holdings, Inc. | -3.45 Million USD | 30634.98% |
| Marker Therapeutics, Inc. | -15.11 Million USD | 7076.65% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 3990.306% |
| Chemomab Therapeutics Ltd. | -8.97 Million USD | 11845.396% |
| Scopus BioPharma Inc. | -124.57 Thousand USD | 846395.806% |
| RAPT Therapeutics, Inc. | -40.57 Million USD | 2698.524% |
| Ainos, Inc. | 4.07 Million USD | -25753.154% |
| Pluri Inc. | 22.82 Million USD | -4518.13% |
| Prothena Corporation plc | -608.34 Million USD | 273.301% |
| Adaptimmune Therapeutics plc | -118.75 Million USD | 987.764% |
| Celularity Inc. | 65.19 Million USD | -1517.231% |
| Rallybio Corporation | -24.1 Million USD | 4474.214% |
| Cue Biopharma, Inc. | -33.81 Million USD | 3217.399% |
| MeiraGTx Holdings plc | -40.3 Million USD | 2715.932% |
| Omeros Corporation | 331.17 Million USD | -218.342% |
| Humacyte, Inc. | -22.48 Million USD | 4788.575% |
| Immunocore Holdings plc | -358.59 Million USD | 394.002% |
| Cocrystal Pharma, Inc. | -24.57 Million USD | 4390.022% |
| Cidara Therapeutics, Inc. | -30.9 Million USD | 3511.776% |
| Blueprint Medicines Corporation | 702.83 Million USD | -50.003% |
| CalciMedica, Inc. | -5.53 Million USD | 19164.611% |
| Cabaletta Bio, Inc. | -188.22 Million USD | 660.128% |
| Marinus Pharmaceuticals, Inc. | -10.21 Million USD | 10421.843% |
| Scholar Rock Holding Corporation | -40.03 Million USD | 2733.247% |
| Sana Biotechnology, Inc. | -33.25 Million USD | 3270.46% |
| Pulmatrix, Inc. | -10.41 Million USD | 10220.697% |
| Elicio Therapeutics, Inc. | -5.97 Million USD | 17738.832% |
| Vigil Neuroscience, Inc. | -38.14 Million USD | 2864.074% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 1046.368% |
| Adlai Nortye Ltd. American Depositary Shares | -59.94 Million USD | 1858.763% |
| Cytokinetics, Incorporated | 642.37 Million USD | -64.122% |
| Eloxx Pharmaceuticals, Inc. | -5.82 Million USD | 18205.324% |
| Nutriband Inc. | -251.65 Thousand USD | 419032.515% |
| Protara Therapeutics, Inc. | -34.11 Million USD | 3189.988% |
| Vor Biopharma Inc. | 4.3 Million USD | -24417.977% |
| Roivant Sciences Ltd. | -6.03 Billion USD | 117.467% |
| Evogene Ltd. | -19.63 Million USD | 5469.629% |
| ProKidney Corp. | -56.23 Million USD | 1974.73% |
| Applied Therapeutics, Inc. | -48.67 Million USD | 2266.077% |
| Hoth Therapeutics, Inc. | -9.23 Million USD | 11513.356% |
| BridgeBio Pharma, Inc. | 1.36 Billion USD | 22.702% |
| CorMedix Inc. | -43.05 Million USD | 2548.808% |
| BioLineRx Ltd. | 7.33 Million USD | -14271.224% |
| Tango Therapeutics, Inc. | -27.46 Million USD | 3938.605% |
| Galectin Therapeutics Inc. | 46.14 Million USD | -2184.597% |
| Atai Life Sciences N.V. | -28.55 Million USD | 3791.691% |
| Renovaro Biosciences Inc. | 2.23 Million USD | -47165.604% |
| Aerovate Therapeutics, Inc. | -22.81 Million USD | 4720.762% |
| Zentalis Pharmaceuticals, Inc. | 17.73 Million USD | -5844.59% |
| Sagimet Biosciences Inc. | -75.07 Million USD | 1504.312% |
| MediciNova, Inc. | -50.78 Million USD | 2176.014% |
| Praxis Precision Medicines, Inc. | -78.8 Million USD | 1437.825% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | 4686799.267% |
| GeoVax Labs, Inc. | -6.45 Million USD | 16438.76% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 627.609% |
| Biomea Fusion, Inc. | -166.57 Million USD | 732.931% |
| PTC Therapeutics, Inc. | -178.97 Million USD | 689.062% |
| Mereo BioPharma Group plc | -51.46 Million USD | 2148.365% |
| Cullinan Oncology, Inc. | -94.84 Million USD | 1211.586% |
| Syndax Pharmaceuticals, Inc. | -293.75 Million USD | 458.89% |
| Absci Corporation | -72.59 Million USD | 1552.207% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | -22989.641% |
| 4D Molecular Therapeutics, Inc. | -234.43 Million USD | 549.704% |
| Dyne Therapeutics, Inc. | -94.21 Million USD | 1219.055% |
| Kiniksa Pharmaceuticals, Ltd. | -95.69 Million USD | 1201.69% |
| Ventyx Biosciences, Inc. | -39.07 Million USD | 2798.214% |
| Allakos Inc. | -24.97 Million USD | 4321.313% |
| Imunon, Inc. | -4.21 Million USD | 25119.222% |
| Fulcrum Therapeutics, Inc. | -14.74 Million USD | 7251.492% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 878.636% |
| BioAtla, Inc. | -109.01 Million USD | 1067.125% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | -143130.77% |
| Bio-Path Holdings, Inc. | -939 Thousand USD | 112376.145% |
| Allogene Therapeutics, Inc. | 11.96 Million USD | -8710.572% |
| Larimar Therapeutics, Inc. | -21.2 Million USD | 5072.282% |
| XOMA Corporation | -29 Million USD | 3735.424% |
| Kezar Life Sciences, Inc. | -16.56 Million USD | 6466.383% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 11793.356% |
| aTyr Pharma, Inc. | -7.44 Million USD | 14253.215% |
| Aligos Therapeutics, Inc. | -124.63 Million USD | 945.882% |
| Akero Therapeutics, Inc. | -208.16 Million USD | 606.463% |
| Viridian Therapeutics, Inc. | -81.77 Million USD | 1389.173% |
| Eliem Therapeutics, Inc. | -92.76 Million USD | 1236.523% |
| EyeGate Pharmaceuticals, Inc. | -859.18 Thousand USD | 122806.312% |
| Akari Therapeutics, Plc | -3.84 Million USD | 27519.324% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | -64862.69% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 23.652% |
| Lexaria Bioscience Corp. | -1.18 Million USD | 88833.435% |
| UroGen Pharma Ltd. | 4.39 Million USD | -23909.861% |
| Sutro Biopharma, Inc. | 113.48 Million USD | -829.03% |
| ZIVO Bioscience, Inc. | 71.96 Thousand USD | -1464941.272% |
| Orgenesis Inc. | 21.78 Million USD | -4739.667% |
| Entera Bio Ltd. | -10.62 Million USD | 10018.835% |
| GH Research PLC | -78.07 Million USD | 1450.299% |
| Lisata Therapeutics, Inc. | -22.28 Million USD | 4830.227% |
| Reneo Pharmaceuticals, Inc. | -26.65 Million USD | 4054.661% |
| Xencor, Inc. | 29.64 Million USD | -3456.446% |
| 60 Degrees Pharmaceuticals, Inc. | -1.96 Million USD | 53621.504% |
| Replimune Group, Inc. | 1.41 Million USD | -74565.227% |
| Coeptis Therapeutics Holdings, Inc. | -244.9 Thousand USD | 430577.159% |
| Vanda Pharmaceuticals Inc. | -126.41 Million USD | 933.965% |
| Lexaria Bioscience Corp. | -1.18 Million USD | 88833.435% |
| Portage Biotech Inc. | -4.98 Million USD | 21265.89% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | 4686799.267% |
| Olema Pharmaceuticals, Inc. | -66.12 Million USD | 1694.436% |
| OncoCyte Corporation | -6.56 Million USD | 16163.888% |
| Qualigen Therapeutics, Inc. | 897.41 Thousand USD | -117379.132% |
| Processa Pharmaceuticals, Inc. | -4.55 Million USD | 23242.134% |
| Purple Biotech Ltd. | -14.13 Million USD | 7557.017% |
| CollPlant Biotechnologies Ltd. | -23.75 Million USD | 4537.923% |
| scPharmaceuticals Inc. | -6.54 Million USD | 16208.067% |
| ProMIS Neurosciences, Inc. | -16.69 Million USD | 6415.975% |
| HilleVax, Inc. | -165.48 Million USD | 737.081% |
| NeuroSense Therapeutics Ltd. | -2.53 Million USD | 41639.519% |
| Tharimmune, Inc. | -10.93 Million USD | 9740.961% |
| Genprex, Inc. | -6.73 Million USD | 15747.537% |
| Neumora Therapeutics, Inc. Common Stock | -368.8 Million USD | 385.86% |
| Atossa Therapeutics, Inc. | -88.46 Million USD | 1291.808% |
| XTL Biopharmaceuticals Ltd. | -1.4 Million USD | 75351.463% |
| Virios Therapeutics, Inc. | -3.31 Million USD | 31884.449% |
| OKYO Pharma Limited | -826.84 Thousand USD | 127605.055% |
| Savara Inc. | 153 Thousand USD | -688967.32% |
| Curis, Inc. | -23.88 Million USD | 4513.585% |
| Daré Bioscience, Inc. | -5.15 Million USD | 20539.922% |
| Carmell Therapeutics Corporation | -776.01 Thousand USD | 135957.822% |
| Titan Pharmaceuticals, Inc. | -6.2 Million USD | 17082.49% |
| Achieve Life Sciences, Inc. | 1.18 Million USD | -88868.186% |
| BeiGene, Ltd. | -2.25 Billion USD | 146.792% |
| Kiromic BioPharma, Inc. | 12.33 Million USD | -8444.58% |
| Revolution Medicines, Inc. Warrant | -608.2 Million USD | 273.342% |
| Protagonist Therapeutics, Inc. | -185.58 Million USD | 668.078% |
| Erasca, Inc. | -37.21 Million USD | 2932.849% |
| bluebird bio, Inc. | 108.57 Million USD | -871.045% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | 81960.294% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | -178.357% |
| DBV Technologies S.A. | -126.98 Million USD | 930.228% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | 81960.294% |
| Moderna, Inc. | -2.9 Billion USD | 136.267% |
| Vincerx Pharma, Inc. | -10.35 Million USD | 10284.245% |
| Fresh Tracks Therapeutics, Inc. | -10.86 Million USD | 9800.709% |
| Molecular Templates, Inc. | 707 Thousand USD | -149019.236% |
| Acrivon Therapeutics, Inc. Common Stock | -31.37 Million USD | 3460.661% |
| Travere Therapeutics, Inc. | 346.6 Million USD | -204.169% |
| Monte Rosa Therapeutics, Inc. | -82.06 Million USD | 1384.727% |
| Spruce Biosciences, Inc. | -91.73 Million USD | 1249.322% |
| Celldex Therapeutics, Inc. | -32.27 Million USD | 3366.835% |
| Cogent Biosciences, Inc. | -34.37 Million USD | 3166.887% |
| MacroGenics, Inc. | -66.98 Million USD | 1673.894% |
| RenovoRx, Inc. | -1.17 Million USD | 89978.346% |
| Adicet Bio, Inc. | -138.78 Million USD | 859.634% |
| Prime Medicine, Inc. | -27.94 Million USD | 3873.211% |
| Aditxt, Inc. | 18.12 Million USD | -5718.0% |
| Adagene Inc. | -87.62 Million USD | 1303.132% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | 25410.076% |
| Quantum-Si incorporated | -118.55 Million USD | 989.254% |
| Maravai LifeSciences Holdings, Inc. | 36 Million USD | -2828.129% |
| Acurx Pharmaceuticals, Inc. | -7.47 Million USD | 14205.519% |
| Voyager Therapeutics, Inc. | -48.5 Million USD | 2273.355% |
| SciSparc Ltd. | -2.06 Million USD | 51154.383% |
| Vericel Corporation | 1.27 Million USD | -82458.575% |
| Revelation Biosciences, Inc. | -11.99 Million USD | 8891.689% |
| Minerva Neurosciences, Inc. | 41 Million USD | -2471.131% |
| Generation Bio Co. | 31.44 Million USD | -3252.433% |
| Astria Therapeutics, Inc. | -175.36 Million USD | 701.191% |
| Black Diamond Therapeutics, Inc. | -30.92 Million USD | 3509.349% |
| Arcutis Biotherapeutics, Inc. | 116.59 Million USD | -804.234% |
| Invivyd, Inc. | -198.47 Million USD | 631.184% |
| Relay Therapeutics, Inc. | -90.27 Million USD | 1267.911% |
| Quoin Pharmaceuticals, Ltd. | -2.39 Million USD | 44070.395% |
| Spero Therapeutics, Inc. | -70.79 Million USD | 1589.297% |
| Artelo Biosciences, Inc. | -6.82 Million USD | 15547.223% |
| 2seventy bio, Inc. | 181.71 Million USD | -480.179% |
| ADMA Biologics, Inc. | 90.06 Million USD | -1070.556% |
| Clene Inc. | 3.34 Million USD | -31465.06% |
| Capricor Therapeutics, Inc. | -9.08 Million USD | 11707.481% |
| Boundless Bio, Inc. Common Stock | -21.51 Million USD | 5001.088% |
| GeoVax Labs, Inc. | -6.45 Million USD | 16438.76% |
| Recursion Pharmaceuticals, Inc. | -344.12 Million USD | 406.364% |
| Citius Pharmaceuticals, Inc. | -25.99 Million USD | 4154.946% |
| Contineum Therapeutics, Inc. Class A Common Stock | 177.66 Million USD | -493.402% |
| Relmada Therapeutics, Inc. | -4.09 Million USD | 25866.974% |
| Finch Therapeutics Group, Inc. | 5 Million USD | -20977.029% |
| ALX Oncology Holdings Inc. | -5.2 Million USD | 20339.451% |
| Vir Biotechnology, Inc. | -130.3 Million USD | 909.087% |
| Evaxion Biotech A/S | 5.28 Million USD | -19841.443% |
| Ocular Therapeutix, Inc. | -112.56 Million USD | 1036.565% |
| Verve Therapeutics, Inc. | -131.27 Million USD | 903.115% |
| Trevena, Inc. | 2.25 Million USD | -46590.567% |
| Surrozen, Inc. | -32.66 Million USD | 3327.63% |
| Tyra Biosciences, Inc. | -51.51 Million USD | 2146.735% |
| Cingulate Inc. | 3.08 Million USD | -34099.851% |
| Galmed Pharmaceuticals Ltd. | -2.93 Million USD | 35996.255% |
| Unity Biotechnology, Inc. | 7.18 Million USD | -14569.167% |
| Tenax Therapeutics, Inc. | -9.29 Million USD | 11446.973% |
| Terns Pharmaceuticals, Inc. | -79.32 Million USD | 1429.089% |
| ACADIA Pharmaceuticals Inc. | -131.45 Million USD | 902.021% |
| Connect Biopharma Holdings Limited | -105.54 Million USD | 1098.913% |
| Clearmind Medicine Inc. | -3.94 Million USD | 26840.301% |
| Kronos Bio, Inc. | -36.05 Million USD | 3024.15% |
| Bolt Biotherapeutics, Inc. | 9.4 Million USD | -11104.942% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | -72203.236% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 2043.145% |
| Statera Biopharma, Inc. | 14.41 Million USD | -7213.009% |
| ImmunityBio, Inc. | 618.22 Million USD | -70.533% |
| Korro Bio, Inc. | -132.94 Million USD | 893.026% |
| Kineta, Inc. | -4.54 Million USD | 23316.758% |
| BioVie Inc. | -17.73 Million USD | 6045.478% |
| Codexis, Inc. | -43.27 Million USD | 2536.442% |
| Celularity Inc. | 65.19 Million USD | -1517.231% |
| Crinetics Pharmaceuticals, Inc. | -3.16 Million USD | 33368.318% |
| Celcuity Inc. | 6.78 Million USD | -15441.706% |
| Virax Biolabs Group Limited | -3.36 Million USD | 31431.071% |
| Cibus, Inc. | -8.07 Million USD | 13151.164% |
| Eledon Pharmaceuticals, Inc. | -4.22 Million USD | 25029.605% |
| eFFECTOR Therapeutics, Inc. | 4.57 Million USD | -22969.431% |
| IN8bio, Inc. | -16.38 Million USD | 6532.809% |
| Kodiak Sciences Inc. | -103.87 Million USD | 1114.944% |
| Annexon, Inc. | -193.75 Million USD | 644.127% |
| Adverum Biotechnologies, Inc. | 36 Thousand USD | -2928436.111% |
| Assembly Biosciences, Inc. | -17.49 Million USD | 6124.761% |
| Avalo Therapeutics, Inc. | -3.51 Million USD | 30110.618% |
| Eyenovia, Inc. | 1.25 Million USD | -83658.745% |
| Puma Biotechnology, Inc. | 26.9 Million USD | -3818.502% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | 32609.189% |
| Xilio Therapeutics, Inc. | -33.24 Million USD | 3271.032% |
| Arcellx, Inc. | -296.95 Million USD | 455.024% |
| Cardiff Oncology, Inc. | -19.5 Million USD | 5504.865% |
| Enanta Pharmaceuticals, Inc. | -58.87 Million USD | 1890.697% |
| Regulus Therapeutics Inc. | -20.72 Million USD | 5186.472% |
| Moolec Science SA | 117.61 Thousand USD | -896268.691% |
| Acumen Pharmaceuticals, Inc. | -38.39 Million USD | 2845.574% |
| Geron Corporation | 14.76 Million USD | -7042.287% |
| LAVA Therapeutics N.V. | -37.91 Million USD | 2880.402% |
| Royalty Pharma plc | 5.65 Billion USD | 81.368% |
| Atea Pharmaceuticals, Inc. | -141.42 Million USD | 845.485% |
| Greenwich LifeSciences, Inc. | -6.98 Million USD | 15183.832% |
| TFF Pharmaceuticals, Inc. | -5.36 Million USD | 19758.786% |
| Mersana Therapeutics, Inc. | -140.73 Million USD | 849.141% |
| Humacyte, Inc. | -22.48 Million USD | 4788.575% |
| Structure Therapeutics Inc. | -124.33 Million USD | 947.902% |
| 89bio, Inc. | -289.05 Million USD | 464.733% |
| PMV Pharmaceuticals, Inc. | -25.24 Million USD | 4276.662% |
| Avenue Therapeutics, Inc. | -1.78 Million USD | 59229.164% |
| Genelux Corporation | -6.89 Million USD | 15381.534% |
| Trevi Therapeutics, Inc. | -31.05 Million USD | 3494.42% |
| Lexicon Pharmaceuticals, Inc. | 83.59 Million USD | -1161.107% |
| Notable Labs, Ltd. | -9.77 Million USD | 10884.298% |
| Liquidia Corporation | -80.17 Million USD | 1414.948% |
| Mustang Bio, Inc. | -3.73 Million USD | 28319.299% |
| Immunovant, Inc. | -635.22 Million USD | 265.968% |
| Quantum-Si incorporated | -118.55 Million USD | 989.254% |
| Arbutus Biopharma Corporation | -17.56 Million USD | 6102.465% |
| DiaMedica Therapeutics Inc. | -4.14 Million USD | 25547.091% |
| Vera Therapeutics, Inc. | 8.02 Million USD | -13034.085% |
| Acasti Pharma Inc. | -23 Million USD | 4682.799% |
| MiNK Therapeutics, Inc. | -3.36 Million USD | 31409.81% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | 6588.085% |
| Xenon Pharmaceuticals Inc. | -137.74 Million USD | 865.408% |
| Elevai Labs, Inc. Common Stock | -3.11 Million USD | 33930.248% |
| NeuroBo Pharmaceuticals, Inc. | -22.23 Million USD | 4842.142% |
| Tempest Therapeutics, Inc. | -18.56 Million USD | 5777.597% |
| Soleno Therapeutics, Inc. | -169.27 Million USD | 722.806% |
| PepGen Inc. | -60.67 Million USD | 1837.717% |
| Moleculin Biotech, Inc. | -22.97 Million USD | 4688.584% |
| United Therapeutics Corporation | -507.7 Million USD | 307.657% |
| Nuvectis Pharma, Inc. | -19.12 Million USD | 5612.25% |
| Solid Biosciences Inc. | -47.75 Million USD | 2307.902% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | 122392.826% |
| Immuneering Corporation | -54.94 Million USD | 2018.854% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | 25180.909% |
| Silo Pharma, Inc. | -3.52 Million USD | 30014.326% |
| Belite Bio, Inc | -87.27 Million USD | 1308.045% |
| XOMA Corporation | -29 Million USD | 3735.424% |
| ARS Pharmaceuticals, Inc. | -70.69 Million USD | 1591.256% |
| Bionomics Limited | 227 Million USD | -364.417% |
| Apogee Therapeutics, Inc. | -116.28 Million USD | 1006.652% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | 41721.516% |
| uniQure N.V. | -102.95 Million USD | 1124.053% |
| Cassava Sciences, Inc. | -121.13 Million USD | 970.322% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | 25410.076% |
| Poseida Therapeutics, Inc. | 40.95 Million USD | -2474.474% |
| Forte Biosciences, Inc. | -11.96 Million USD | 8914.255% |
| Anebulo Pharmaceuticals, Inc. | -3.09 Million USD | 34172.555% |
| Enlivex Therapeutics Ltd. | 106 Thousand USD | -994497.17% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | 32609.189% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | -11739.113% |
| FibroBiologics, Inc. Common Stock | -7.41 Million USD | 14316.195% |
| Altimmune, Inc. | -134.48 Million USD | 883.922% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | -432.286% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | 41721.516% |
| Compugen Ltd. | -12.9 Million USD | 8270.126% |
| Peak Bio, Inc. | 10.34 Million USD | -10095.908% |
| Zevra Therapeutics, Inc. | -283 Thousand USD | 372634.629% |
| Benitec Biopharma Inc. | -50.58 Million USD | 2184.285% |
| Spyre Therapeutics, Inc. | -104.33 Million USD | 1110.44% |
| NKGen Biotech, Inc. Common Stock | 19.64 Million USD | -5266.623% |
| Zura Bio Limited | -99.8 Million USD | 1156.322% |
| PolyPid Ltd. | 6.17 Million USD | -16987.083% |
| Aileron Therapeutics, Inc. | 74.12 Million USD | -1322.387% |
| NKGen Biotech, Inc. Warrants | 19.64 Million USD | -5266.623% |
| Instil Bio, Inc. | 75.35 Million USD | -1299.019% |
| argenx SE | -2.02 Billion USD | 151.964% |
| Immunome, Inc. | -97.02 Million USD | 1186.555% |
| Compass Therapeutics, Inc. | -22.49 Million USD | 4786.699% |
| Verona Pharma plc | -220.44 Million USD | 578.252% |
| enGene Holdings Inc. Warrants | -71.74 Million USD | 1569.513% |
| Shattuck Labs, Inc. | -121.42 Million USD | 968.258% |
| CervoMed Inc. | -7.79 Million USD | 13628.729% |
| LENZ Therapeutics, Inc. | -185.49 Million USD | 668.344% |
| Plus Therapeutics, Inc. | -4.37 Million USD | 24208.69% |
| Dianthus Therapeutics, Inc. | -131.73 Million USD | 900.268% |
| Moolec Science SA | 117.61 Thousand USD | -896268.691% |
| Enveric Biosciences, Inc. | -2.28 Million USD | 46178.829% |
| Inovio Pharmaceuticals, Inc. | 15.89 Million USD | -6531.323% |
| AnaptysBio, Inc. | -18.15 Million USD | 5908.347% |
| Design Therapeutics, Inc. | -18.15 Million USD | 5908.667% |
| Leap Therapeutics, Inc. | -70.38 Million USD | 1597.951% |
| NeurAxis, Inc. | 145.7 Thousand USD | -723491.627% |
| Seelos Therapeutics, Inc. | 11.23 Million USD | -9286.334% |
| Lumos Pharma, Inc. | -28.49 Million USD | 3800.112% |
| Achilles Therapeutics plc | -126.92 Million USD | 930.633% |
| enGene Holdings Inc. Common Stock | -71.74 Million USD | 1569.513% |
| 180 Life Sciences Corp. | -655.73 Thousand USD | 160878.522% |
| Opiant Pharmaceuticals, Inc. | -20.77 Million USD | 5175.007% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | -72203.236% |
| Nutriband Inc. | -251.65 Thousand USD | 419032.515% |
| ORIC Pharmaceuticals, Inc. | -13.17 Million USD | 8104.502% |
| CG Oncology, Inc. Common stock | -7.44 Million USD | 14270.336% |
| Fractyl Health, Inc. Common Stock | 340.19 Million USD | -209.901% |
| Rani Therapeutics Holdings, Inc. | 23.73 Million USD | -4341.85% |
| MoonLake Immunotherapeutics | -447.47 Million USD | 335.607% |
| Palisade Bio, Inc. | -12.06 Million USD | 8839.725% |
| Tourmaline Bio, Inc. | -140.31 Million USD | 851.383% |
| Beam Therapeutics Inc. | -262.72 Million USD | 501.288% |
| Neurogene Inc. | -131.95 Million USD | 898.964% |
| Mirum Pharmaceuticals, Inc. | 21.81 Million USD | -4732.568% |
| AEON Biopharma, Inc. | -4.88 Million USD | 21703.955% |
| CARGO Therapeutics, Inc. Common Stock | -377.19 Million USD | 379.506% |
| Sesen Bio, Inc. | -112.55 Million USD | 1036.69% |
| Enliven Therapeutics, Inc. | -99.86 Million USD | 1155.751% |
| Kiora Pharmaceuticals, Inc. | -2.34 Million USD | 45004.853% |
| Iovance Biotherapeutics, Inc. | -39.02 Million USD | 2801.463% |
| Taysha Gene Therapies, Inc. | -83.28 Million USD | 1365.907% |
| Athira Pharma, Inc. | -88.99 Million USD | 1284.59% |
| Vaccinex, Inc. | -1.28 Million USD | 81953.494% |
| HCW Biologics Inc. | 2.85 Million USD | -36805.585% |
| XOMA Corporation | -29 Million USD | 3735.424% |
| Nektar Therapeutics | 210.24 Million USD | -401.462% |
| Arvinas, Inc. | -313.8 Million USD | 435.97% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | -64862.69% |
| Merus N.V. | -192.88 Million USD | 646.584% |
| Omega Therapeutics, Inc. | 59.98 Million USD | -1657.561% |
| Quince Therapeutics, Inc. | -6.93 Million USD | 15295.633% |
| Rezolute, Inc. | -68.16 Million USD | 1646.581% |
| Clene Inc. | 3.34 Million USD | -31465.06% |
| Indaptus Therapeutics, Inc. | -13.18 Million USD | 8094.79% |
| BeyondSpring Inc. | -13.75 Million USD | 7764.653% |
| Synlogic, Inc. | -6.68 Million USD | 15870.726% |
| Allarity Therapeutics, Inc. | 1.13 Million USD | -92869.4% |
| Phio Pharmaceuticals Corp. | -8.45 Million USD | 12569.225% |
| Peak Bio, Inc. | 10.34 Million USD | -10095.908% |
| Werewolf Therapeutics, Inc. | -82.42 Million USD | 1379.147% |
| Krystal Biotech, Inc. | -350.23 Million USD | 401.02% |
| Karyopharm Therapeutics Inc. | 124.12 Million USD | -749.364% |
| SpringWorks Therapeutics, Inc. | -168.99 Million USD | 723.845% |
| Lipella Pharmaceuticals Inc. | -3.15 Million USD | 33493.25% |
| MannKind Corporation | 143.89 Million USD | -632.648% |
| Ikena Oncology, Inc. | -109.15 Million USD | 1065.841% |
| Cyclerion Therapeutics, Inc. | -7.57 Million USD | 14025.149% |
| Gyre Therapeutics, Inc. | -33.1 Million USD | 3285.115% |
| Gossamer Bio, Inc. | 180.35 Million USD | -484.554% |
| CohBar, Inc. | -5.93 Million USD | 17876.443% |
| Cognition Therapeutics, Inc. | -29.74 Million USD | 3644.013% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | -22989.641% |
| Legend Biotech Corporation | -949.39 Million USD | 211.046% |
| Mural Oncology plc | -255.84 Million USD | 512.078% |
| Biora Therapeutics, Inc. | 32.21 Million USD | -3172.615% |
| PaxMedica, Inc. Common Stock | -4.71 Million USD | 22480.665% |
| Disc Medicine, Inc. | -358.28 Million USD | 394.259% |
| Champions Oncology, Inc. | 4.81 Million USD | -21809.248% |
| REGENXBIO Inc. | 54.76 Million USD | -1824.98% |
| Ensysce Biosciences, Inc. | -268.9 Thousand USD | 392158.593% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 798.083% |
| Cellectar Biosciences, Inc. | -9.01 Million USD | 11798.539% |
| Edgewise Therapeutics, Inc. | -80.68 Million USD | 1406.685% |
| Vaxart, Inc. | -8.24 Million USD | 12893.023% |
| PharmaCyte Biotech, Inc. | -50.17 Million USD | 2200.984% |
| Aldeyra Therapeutics, Inc. | -127.16 Million USD | 929.055% |
| Cellectis S.A. | -43.85 Million USD | 2503.997% |
| Longeveron Inc. | -2.9 Million USD | 36354.23% |
| Repare Therapeutics Inc. | -107.85 Million USD | 1077.464% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | -8.87% |
| Inozyme Pharma, Inc. | 12 Million USD | -8682.681% |
| Revolution Medicines, Inc. | -608.2 Million USD | 273.342% |
| Nymox Pharmaceutical Corporation | -1.23 Million USD | 85813.252% |
| Third Harmonic Bio, Inc. | -265.11 Million USD | 497.663% |
| ArriVent BioPharma, Inc. Common Stock | -150.07 Million USD | 802.511% |
| AN2 Therapeutics, Inc. | -15.64 Million USD | 6837.86% |
| Anixa Biosciences, Inc. | -740 Thousand USD | 142569.324% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 111.023% |
| Denali Therapeutics Inc. | -74.86 Million USD | 1508.232% |
| Revelation Biosciences, Inc. | -11.99 Million USD | 8891.689% |
| Veru Inc. | 4.77 Million USD | -21956.064% |
| Corvus Pharmaceuticals, Inc. | -11.24 Million USD | 9474.649% |
| Cingulate Inc. | 3.08 Million USD | -34099.851% |
| Passage Bio, Inc. | 4.58 Million USD | -22893.959% |
| Context Therapeutics Inc. | -14.44 Million USD | 7396.094% |
| Exicure, Inc. | 5.84 Million USD | -17924.842% |
| Day One Biopharmaceuticals, Inc. | -230.37 Million USD | 557.631% |
| Oramed Pharmaceuticals Inc. | -39.57 Million USD | 2764.324% |
| Scinai Immunotherapeutics Ltd. | 15.69 Million USD | -6618.966% |
| Rhythm Pharmaceuticals, Inc. | -58.82 Million USD | 1892.341% |
| Nuvalent, Inc. | -335.38 Million USD | 414.345% |
| ABVC BioPharma, Inc. | 1.73 Million USD | -60688.103% |
| Carisma Therapeutics, Inc. | -74.48 Million USD | 1515.474% |
| Unicycive Therapeutics, Inc. | -8.89 Million USD | 11959.089% |
| OmniAb, Inc. | 9.2 Million USD | -11355.754% |
| Anew Medical, Inc. | 1.43 Million USD | -73498.517% |
| Fennec Pharmaceuticals Inc. | 16.38 Million USD | -6335.654% |
| Lipocine Inc. | -4.75 Million USD | 22273.785% |
| Lexeo Therapeutics, Inc. Common Stock | -109.82 Million USD | 1059.931% |
| Nautilus Biotechnology, Inc. | 15.23 Million USD | -6821.89% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 2181.117% |
| G1 Therapeutics, Inc. | 24.89 Million USD | -4135.389% |
| Bellerophon Therapeutics, Inc. | -6.72 Million USD | 15786.252% |
| Sage Therapeutics, Inc. | -65.82 Million USD | 1701.581% |
| Ocugen, Inc. | -32.52 Million USD | 3341.822% |
| Mind Medicine (MindMed) Inc. | -85.57 Million USD | 1331.987% |
| Q32 Bio Inc. | -37.94 Million USD | 2878.204% |
| Brainstorm Cell Therapeutics Inc. | -628 Thousand USD | 167977.866% |
| Alumis Inc. Common Stock | -13.52 Million USD | 7892.69% |
| Equillium, Inc. | -22.39 Million USD | 4808.257% |
| Kyverna Therapeutics, Inc. | -25.56 Million USD | 4223.408% |
| Coya Therapeutics, Inc. | -32.62 Million USD | 3331.313% |
| CNS Pharmaceuticals, Inc. | -247.91 Thousand USD | 425355.834% |
| Galera Therapeutics, Inc. | 134.04 Million USD | -686.524% |
| Evelo Biosciences, Inc. | 3.19 Million USD | -32866.635% |
| Comera Life Sciences Holdings, Inc. | 328.44 Thousand USD | -320893.116% |
| Dominari Holdings Inc. | 195 Thousand USD | -540552.821% |
| Edesa Biotech, Inc. | -5.26 Million USD | 20116.917% |
| vTv Therapeutics Inc. | -8.91 Million USD | 11923.18% |
| Bio-Techne Corporation | 267.74 Million USD | -293.757% |
| Agios Pharmaceuticals, Inc. | -16.2 Million USD | 6604.245% |
| Harmony Biosciences Holdings, Inc. | -118.09 Million USD | 992.741% |
| Prelude Therapeutics Incorporated | -8.4 Million USD | 12646.388% |
| Candel Therapeutics, Inc. | -12.65 Million USD | 8433.515% |
| iTeos Therapeutics, Inc. | -245.11 Million USD | 530.107% |
| Nkarta, Inc. | 57.29 Million USD | -1739.95% |
| BioCardia, Inc. | 212 Thousand USD | -497198.585% |
| Iterum Therapeutics plc | 13.43 Million USD | -7745.461% |